Brazil's Medical Future Brightens As Fiocruz Signs Radiopharma Agreement

In collaboration with the University of Coimbra in Portugal, Fiocruz has inked a deal to advance the technological development of radiopharmaceuticals and secure future health registrations for these products in Brazil. This partnership is facilitated through the Institute of Drug Technology (Farmanguinhos/Fiocruz) and was formalized on July 19 in Coimbra. Additionally, two other agreements were signed during the event: one focusing on education and the other concerning the health registration of Farmanguinhos products in Portugal.

Fiocruz President, Mario Moreira said in a statement, “I am sure that our Unified Health System (SUS, in the Portuguese acronym) will benefit from the technological development of radiopharmaceuticals, and that we can contribute to the Portuguese health system by supplying medicines produced by Fiocruz and registered in Portugal. The agreements being signed today also had the crucial support of our Anvisa, which is committed to expanding access to available treatments for the population of both countries.”